



**MOREPEN**

**Q4'FY25**  
**INVESTOR**  
**PRESENTATION**

**MOREPEN LABORATORIES LIMITED**



# SAFE HARBOUR

This investor presentation has been prepared for general information purposes in respect of Morepen Laboratories Limited ("Company") together with its subsidiary, as applicable (together, with the Company, the "Group") only, without regard to any specific objectives, suitability, financial situations and needs of any particular person and does not constitute a prospectus or placement memorandum or any recommendation or form part of any offer or invitation, directly or indirectly, in any manner, or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company in any jurisdiction, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment therefor. This presentation does not solicit any action based on the material contained herein. Nothing in this presentation is intended by the Group to be construed as legal, accounting or tax advice.

The information is confidential, and is intended only for the exclusive use of the recipients thereof, and may not be retained by you and neither this presentation nor any part thereof may be (i) copied, photocopied, duplicated or otherwise reproduced in any forms or by any means; or (ii) disseminated, reproduced, recirculated, redistributed, published or advertised in any media, website or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. If this document has been received in error, it must be returned immediately to the Company.

Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. Neither this document nor any part or copy of it may be distributed, directly or indirectly, in the United States. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. Accordingly, any persons in possession of this document should inform themselves about and observe any such restrictions. By reviewing this presentation, you agree to be bound by the foregoing limitations. You further represent and agree that you are located outside the United States and you are permitted under the laws of your jurisdiction to receive this presentation. You may not repackage or sell the presentation. Information contained in a presentation hosted or promoted by the Group is provided "as is" without warranty of any kind, either expressed or implied, including any warranty of fitness for a particular purpose.

This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation contains certain forward-looking statements relating to the business, financial performance, strategy, growth prospects and results of the Group and/or the future developments industry and the competitive and regulatory environment in the industry in which it operates. Forward-looking statements are statements concerning future circumstances and results, and any other statements that are not historical facts, sometimes identified by the words including, without limitation "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements, including those cited from third party sources, contained in this presentation are based on numerous assumptions and are uncertain and subject to risks. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Neither the Group nor its affiliates or advisors or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. Forward-looking statements speak only as of the date of this presentation and are not guarantees of future performance. As a result, the Group expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Given these uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them.

The information contained in this presentation and materials are only current as of the dates specified herein and have not been independently verified. None of the Group, its directors, promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise in connection with this presentation, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

Past performance is not a guide for future performance. The Group undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise. Any person/ party intending to provide finance/ invest in the shares/ businesses of the Group shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. Further, you will be solely responsible for forming your own view of the potential future performance of the business of the Company.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer to sell or a solicitation of any offer to buy the securities of the Company in the United States or in any other jurisdiction where such offer or sale would be unlawful. Securities may not be offered, sold, resold, pledged, delivered, distributed or transferred in to or within the United States absent registration under the United States Securities Act of 1933, as amended (the "Securities Act"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer and that will contain detailed information about the issuer and management, as well as financial statements. The Company's securities have not been and will not be registered under the Securities Act and will not be offered to the public in the United States.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials come should inform themselves about and observe any such restrictions. By accessing this presentation, you accept this disclaimer and any claims arising out of or in connection with this presentation shall be governed by the laws of India and only the courts in the concerned state in India and no other courts shall have jurisdiction over the same.



A black and white photograph of a woman and a young child. The woman is in the foreground, smiling and looking towards the camera. The child is behind her, also smiling and looking towards the camera. The image is partially obscured by a blue vertical bar on the left side of the slide.

# **1** EXECUTIVE SUMMARY



# 1 EXECUTIVE SUMMARY

## BUSINESS SEGMENTS:



### PHARMA BUSINESS

API+RX+CONSUMER

73%

SHARE OF PHARMA  
BUSINESS



### MEDICAL DEVICES

POINT OF CARE

27%

SHARE OF MEDICAL  
DEVICES



FY  
25





# 1 EXECUTIVE SUMMARY:

## COMPANY POSITIONING:



COMMITMENT &  
CREDIBILITY

#1

MARKET LEADERS IN  
6 APIS

80


EXPORTING TO OVER 80  
COUNTRIES

72%

REVENUE SHARE OF API  
FROM EXPORT

#1

MARKET LEADERS IN  
GLUCO AND BP METERS



FULLY INTEGRATED MFG.  
FOR MEDICAL DEVICES

Rx

INCREASING SHARE OF  
FORMULATION BUSINESS



STRONG PORTFOLIO OF  
CONSUMER HEALTH

FY  
25




# 1 EXECUTIVE SUMMARY


## CONSOLIDATED REVENUE:



ANNUAL REVENUE  
RS. IN CRORES



QUARTERLY REVENUE  
RS. IN CRORES



FY  
25






# 2 PHARMA BUSINESS



# 2 PHARMA BUSINESS



## API & FORWARD INTEGRATION:



API  
B2B BUSINESS

73%

SHARE OF PHARMA  
BUSINESS



RX  
MEDICINES



CONSUMER  
HEALTH

27%

SHARE OF MEDICAL  
DEVICES

FY  
25







## 2 PHARMA BUSINESS

### TOTAL PHARMA REVENUE :

ANNUAL REVENUE  
RS. IN CRORES



QUARTERLY REVENUE  
RS. IN CRORES






# 2 PHARMA BUSINESS/API

## MARKET LEADERSHIP:

<u>PRODUCT</u>	<u>RANK</u>	<u>EXPORT* SHARE</u>
LORATADINE	#1	81%
DESLORATADINE	#1	66%
MONTelukAST	#1	77%
ATORVASTATIN	#4	30%
ROSUVASTATIN	#4	30%
FEXOFENADINE	#3	30%

## PRODUCT SHARE



## API REVENUE SPLIT FY'25

*\*Morepen export share from India as data as per export data*





## 2 PHARMA BUSINESS/API



### NEW PRODUCTS LAUNCHED\*:



#### DIABETICS

- SITAGLIPTIN
- LINAGLIPTIN
- DAPAGLIFLOZIN
- EMPAGLIFLOZIN
- SAXAGLIPTIN
- ERTUGLIFLOZIN

#### CARDIAC

- APIXABAN
- EDOXABAN
- RIVAROXABAN
- OLMESARTAN
- TICAGRELOR 
- BEMPEDOIC ACID 

#### OTHER

- RESMETIROM 
- VONOPRAZAN
- VORTIOXETINE
- BEXPIPRAZOLE

*\*Not available for sales in the countries with valid patent*



## 2 PHARMA BUSINESS/API


### PRODUCT PIPELINE\*:

#### PILOT SCALE

- BARICITINIB
- TAFAMIDIS
- BILASTINE
- FINERENONE
- RUPATADINE
- CARIPRAZINE

#### U/ DEVELOPMENT

- CENOBAMATE
- LISDEXAMFETAMINE (LDF)
- MAVACAMTEN
- VIBEGRON
- UPADACITINIB
- FEZOLINETANT



*\*Not available for sales in the countries with valid patent*






## 2 PHARMA BUSINESS/API

### NEW PRODUCTS:

#### REVENUE SHARE




4.2%

INCREASE IN REVENUE  
CONTRIBUTION OVER 3 YEARS



#### NEW PRODUCT REVENUE

RS. IN CRORES



65%

INCREASE IN NEW PRODUCTS  
REVENUE OVER 3 YEARS


FY  
25

# 2 PHARMA BUSINESS/API

## INCREASING FOCUS ON EXPORT



### EXPORT SHARE (API)




7.6%

INCREASE IN EXPORT  
CONTRIBUTION IN 3 YEARS

### EXPORT REVENUE

RS. IN CRORES



26%

INCREASE IN EXPORT  
REVENUE IN 3 YEARS

FY  
25



# 2 PHARMA BUSINESS/API

## STRONG EXPORT NETWORK:

80

EXPORTING TO OVER 80 COUNTRIES

500

TOP NOTCH CUSOTMERS WORLDWIDE

60%


BUSINESS COMES FROM REPEAT CUSOTMERS



EXPERIENCED SALES TEAM FOR ALL REGIONS



## CONTINENT-WISE SHARE



FY  
25


# 2 PHARMA BUSINESS/API




## REGION WISE PERFORMANCE:

RS. IN CRORES


### USA




### EUROPE




### INDIA\*



### APAC



### MENA & OTHER



FY  
25

\*Including other income







## 2 PHARMA BUSINESS/API

### API REVENUE :

ANNUAL REVENUE  
RS. IN CRORES



QUARTERLY REVENUE  
RS. IN CRORES






## 2 PHARMA BUSINESS/API



### INCREASING SALES VOLUMES :


SALES QUANTITY (MT)



57%

INCREASE IN QUANTITY SOLD  
IN 2 YEARS


AVERAGE SALES PRICE (INR)



-24%

DECREASE IN SALES PRICE  
IN 2 YEARS

REVENUE\* (RS IN CRORES)




19%

INCREASE IN NET SALES  
REVENUE IN 3 YEARS

*\*Including other income*

FY  
25





## 2 PHARMA BUSINESS/API



INSTALLED API CAPACITY:

CAPACITIES

FY23

314 KL

FY24

403 KL

FY25

514 KL



PLANNED FOR FY26

600 KL

91% UP

FY  
25





## 2 PHARMA BUSINESS/ API

### INTELLECTUAL PROPERTY:

168

WORLDWIDE PATENTS  
FILED

55

R&D SCIENTISTS IN  
THE R&D LAB

325

DRUG MASTER FILES  
WORLDWIDE

27

US DMFS AND EUROPE  
CEPS

48


NEW MOLECULES  
DEVELOPED

NIL

'483' OBSERVATION\* FOR LAST  
THREE USFDA INSPECTIONS

30

NEW RX PRODUCTS  
DEVELOPED AND  
LAUNCHED



ENHANCED CHEMISTRY  
SKILLS

# 2 PHARMA BUSINESS/API

## REGULATORY APPROVALS:



UNITED STATES



EUROPE



JAPAN



BRAZIL



CHINA NMPA  
CHINA



KOREA



INDIA WHO GMP



ISO 13485  
(MED DEVICES)

FY  
25





## 2 PHARMA BUSINESS/RX & OTC


INCREASED FOCUS ON B2C

29%  
INCREASE IN REVENUE IN  
Q4'FY25

21%  
INCREASE IN FORMULATION  
REVENUE IN 2 YEARS



RS. IN CRORES



FY  
25



# 2 PHARMA BUSINESS/RX & OTC




TO ADD 1000 MEDICAL REPRESENTATIVES IN 3 years

200

MEDICAL REPRESENTATIVES  
AS ON MARCH 2025

400

MEDICAL REPRESENTATIVES  
PLANNED BY MARCH 26






## 2 PHARMA BUSINESS/RX & OTC



### FIRST TIME IN INDIA- RESTENTIROM

- DEVELOPED IN-HOUSE BY THE MOREPEN R&D TEAM
- GOT CDSCO APPROVAL FOR CONDUCTING BIO STUDIES
- GETTING READY TO CONDUCT BIOEQUIVALENCE STUDIES
- GLOBAL LAUNCH AFTER THE REQUISITE APPROVALS IS PLANNED
- OPEN FOR MARKETING PARTNERS WORLDWIDE




**Morepen gets  
CDSCO nod for  
Liver Drug BE  
studies**

**MOREPEN**  
*The Joy Of Growing Together*

*“Among the first few companies  
in India getting ready for the  
Global Launch”*

**Morepen to conduct BE studies  
for Restmetirom tablets - a new  
unique drug for non-alcoholic  
fatty liver**





# 2 PHARMA BUSINESS/RX & OTC



## TOP RX PRODUCTS

### ANTI INFECTIVE

**Saltum**<sup>®</sup> Cefopen<sup>™</sup> Klarim<sup>®</sup>

### GASTROINTESTINAL

**DOM-DT** **Intebact**<sup>®</sup> **UdoFix**<sup>™</sup> **ACiFiX** **AciFix**<sup>RAFT</sup> SUSPENSION

### MULTI VITAMIN

**Rythmix**<sup>®</sup> **KOMPACT**<sup>®</sup> **LycoMore**<sup>™</sup> Syrup

### CARDIO DIABETIC

**Ticapen**<sup>®</sup> **Apixamore**<sup>™</sup> **Empamore**<sup>™</sup>

FY  
25



# 2 PHARMA BUSINESS/RX & OTC

## TOP OTC PRODUCTS (TRADE)



BURNOL



LEMOLATE



PAIN-X



SEXUAL WELLNESS



ACIDITY X



ORAL HEALTH



ORS RANGE



FEVER-X

FY 25



# 2 PHARMA BUSINESS/RX & OTC

## TOP OTC PRODUCTS (ONLINE)



WEIGHT MANGEMENT



OMEGA-3



SEXUALL WELLNESS



SEXUAL WELLNESS




COD LIVER



BIOTIN



SKIN COLLAGEN



MULTIVITAMINS

FY 25





# 2 PHARMA BUSINESS/RX & OTC

## TOP OTC PRODUCTS (NUTRITION)



WHEY PROTEIN




TURBO WHEY PROTIEN



PRE WORKOUT



RAPTOR



ISOTONIC



EAA +BCAA

A black and white photograph of a smiling woman and a young child, with the woman's face in the foreground and the child's face slightly behind her, both looking towards the camera. The image is partially obscured by a blue bar at the top and a teal bar at the bottom.

# 3 MEDICAL DEVICES





# 3 MEDICAL DEVICES

## MARKET LEADERSHIP:



#1

MARKET LEADERS FOR  
BLOOD GLUCOSE METERS

#1

MARKET LEADERS FOR  
BP MONITORS

25 yr


OF FOCUSED CUSTOMER  
SERVICE



OWN MANUFACTURING  
SINCE 10 YEARS

14m

14 MILLION METERS INSTALLED,  
REPEAT CUSTOMERS



FULLY BACKWARD INTEGRATED  
SUPPLY CHAIN



ALL INDIA DISTRIBUTION  
AND SERVICE

ISO

ISO-13485 APPROVED  
FACILITIES

FY  
25





# 3 MEDICAL DEVICES

## TOP SELLING PRODUCTS:




BLOOD GLUCOSE METERS



BP MONITORS



NEBULISERS



THERMOMETERS



ORTHO SUPPORTS



STETHOSCOPE




PREGNANCY KITS




# 3 MEDICAL DEVICES

## TOTAL REVENUE :

ANNUAL REVENUE  
RS. IN CRORES



QUARTERLY REVENUE  
RS. IN CRORES








# 3 MEDICAL DEVICES


## GLUCOMETER REVENUE :




CUMULATIVE  
METER BASE  
(millions)



NO. OF STRIPS  
SOLD  
(millions)



ANNUAL REVENUE  
RS. IN CRORES




FY  
25

# 3 MEDICAL DEVICES




## BP MONITOR REVENUE :

NO. OF BP METERS SOLD  
(millions)



ANNUAL REVENUE  
RS. IN CRORES



FY  
25










# 3 MEDICAL DEVICES

## CAPACITY EXPANSION:



NO. OF UNITS PER ANNUM





# 3 MEDICAL DEVICES

## GROWTH DRIVERS:




INCREASING HEALTH  
AWARENESS



GROWING HEALTH  
CONCERNS



HIGHER DISPOSABLE  
INCOME



ADVANCED PRODUCTS  
AND TREATMENTS

\$234bn

GLOBAL MEDICAL DEVICES  
MARKET BY 2032

12.7%

CAGR GROWTH RATE

212m

HIGHEST DIABETIC  
POPULATION IN INDIA

62%

REMAIN UNDIAGNOSED  
AND UNTREATED


FY  
25






# 3 MEDICAL DEVICES

## DIGITAL MOVES:






**Take control of your health and wellness with Dr. Morepen - Sync**

Log and track your key health metrics like **blood glucose, blood pressure, weight** and much more, effortlessly.

[Download on Android](#) [Download on IOS](#)



BETTER CONNECT WITH THE CUSTOMERS

1.31

LAKH DOWNLOADS AND ENGAGING



DIGITAL HEALTH RECORD READY

FY 25





# 3 MEDICAL DEVICES

## GROWTH DRIVERS:


- Expansion to International markets:



Thailand



Qatar



Oman

- PLANNING ANOTHER 2-3 COUNTRIES IN THE MIDDLE EAST, AFRICA AND ASIA
- GOOD PROGRESS IN THE US MARKET LONG-TERM SUPPLIES WITH CHAIN STORES
- SOON LAUNCHING AT AMAZON.COM (USA) [amazon.com](https://www.amazon.com)





A black and white photograph of a woman and a young child. The woman is in the foreground, smiling and looking towards the camera. The child is behind her, also looking towards the camera with a curious expression. The image is partially obscured by a blue bar at the top and a teal bar at the bottom.

# **4** FINANCIAL OVERVIEW



# 4 FIANCIAL OVERVIEW

## ANNUAL PERFORMANCE:




Rs. 2.20


RS. IN CRORES

ANNUAL EPS- UP 17%


### GROSS REVENUE



### EBITDA



### PAT








# 4 FIANCIAL OVERVIEW

## QUARTERLY PERFORMANCE:




RS. IN CRORES


### GROSS REVENUE



### EBITDA



### PAT



A black and white photograph of a smiling woman with her head tilted back, looking up, with a young child leaning over her shoulder, also looking up. The image is partially obscured by a blue vertical bar on the left and a teal horizontal bar at the bottom.

# 5 ANNEXURES









# INTERNATIONAL EXHIBITIONS (API)



CPHI MILAN




CPHI INDIA




CPHI CHINA



FCE PHARMA  
SÃO PAULO



PHARMA TECH  
EAST AFRICA



CPHI MIDDLE EAST



DCAT WEEK  
NEW YORK



CPHI JAPAN







# INTERNATIONAL EXHIBITIONS (DEVICES)



Medica- Germany



Arab Health - Dubai



Global Health - Saudi





# AWARDS AND RECOGNITION



VISIONARY  
ENTREPRENEUR 2024



FINANCE LEADER  
OF THE YEAR



BRAND ICON OF THE  
YEAR 2024



AWARD 100 SUPPLY  
CHAIN



BEST HEALTHCARE  
COMPANY 2024



ASIA BOOK OF  
RECORDS




MOST INNOVATIVE  
HR AWARD



REPRESENTED AT  
PCSI








# DISTRIBUTION



614

TOTAL SALES FORCE  
ACROSS THE PORTFOLIO



DEDICATED SALES TEAMS  
FOR EACH DIVISION

5.3K

DISTRIBUTORS ALL  
OVER INDIA

FIVE

COMPANY OWNED AND  
OPERATED SERVICE CENTRES

343K

RETAIL TOUCH POINTS ACROSS  
PRODUCT PORTFOLIO



*Note: Map not to scale*






# MANUFACTURING PLANTS




FACILITIES AT PAR WITH INTERNATIONAL STANDARDS:



📍 **BADDI (1998)**

APIS, MED. DEVICES  
FORMULATIONS



📍 **MASULKHANA (1984)**

APIS PRODUCTS



📍 **PARWANOO (1996)**

FORMULATIONS



📍 **PARWANOO (2007)**

FORMULATIONS






# INTEGRATED PHARMA COMPLEX AT BADDI (HP) INDIA











VARUN SURI  
CEO- CONSUMER CARE



ANUBHAV SURI  
CEO-MEDICAL DEVICES



AMITA SHARMA  
COO- API



AJAY SHARMA  
CFO



SENIOR MANAGEMENT



FINANCE TEAM





VIPUL SRIVASTAVA  
COMPANY SECRETARY



VIKAS SHARMA  
HEAD TALENT ACQUISITION



MANJU NATH  
CHIEF OF R&D (DEVICES)



PYUSH TANDON  
VP- SALES & MKTG (API)



VIVAN PRASHAR  
VP- PROJECT & ENGG.



ASHUTOSH SHARMA  
VP- SALES & MKTG (RX)



SUMIT BHATNAGAR  
VP-FINANCE & ACC



NISHANT DOSHI  
VP- CORP FINANCE & IR



SANDEEP ATRI  
DGM - IT



MK SHARMA  
QC/QA



GEETA SACHDEVA  
HR ADVISOR



REKHA BANSAL  
VP -FINANCE (DEVICES/DML)



DEEPAK TALWAR  
GM FINANCE-RX



CHARANJIT CHITKARA  
GM-QC



ESHITA GOSWAMI  
GENERAL MANAGER - MARKETING (OTC  
DIVISION)





Looking Forward to a  
Fruitful Partnership

**THANK YOU**

MOREPEN LABORATORIES LIMITED